OS THERAPIES INCORPORATED Operating Cash Flow
OS THERAPIES INCORPORATED (OSTX) reported Operating Cash Flow of -$10.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- OS THERAPIES INCORPORATED net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$5.53M.
- OS THERAPIES INCORPORATED net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$4.56M.
- OS THERAPIES INCORPORATED net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$3.73M.
- OS THERAPIES INCORPORATED net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$4.71M.
- OS THERAPIES INCORPORATED net cash provided by (used in) operating activities for fiscal 2025 was -$14.24M.
- OS THERAPIES INCORPORATED net cash provided by (used in) operating activities for fiscal 2024 was -$7.28M.
- OS THERAPIES INCORPORATED net cash provided by (used in) operating activities for fiscal 2023 was -$3.01M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$10.10M 10-Q · filed 2026-08-14 | -$13.83M derived: sum of 3 quarters · filed 2026-08-14 | -$18.53M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$4.56M 10-Q · filed 2026-05-18 | -$8.29M derived: sum of 2 quarters · filed 2026-05-18 | -$13.00M derived: sum of 3 quarters · filed 2026-05-18 | -$15.36M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$8.44M derived: sum of 2 quarters · filed 2026-03-31 | -$10.80M derived: sum of 3 quarters · filed 2026-08-14 | -$14.24M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$4.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$7.07M derived: sum of 2 quarters · filed 2026-08-14 | -$10.51M 10-Q · filed 2025-11-14 | -$12.88M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$2.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$5.80M 10-Q · filed 2026-08-14 | -$8.18M derived: sum of 3 quarters · filed 2026-08-14 | -$11.56M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$3.44M 10-Q · filed 2026-05-18 | -$5.82M derived: sum of 2 quarters · filed 2026-05-18 | -$9.20M derived: sum of 3 quarters · filed 2026-05-18 | -$10.08M derived: sum of 4 quarters · filed 2026-05-18 |
| 2024-12-31 | -$2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$5.76M derived: sum of 2 quarters · filed 2026-03-31 | -$6.64M derived: sum of 3 quarters · filed 2026-03-31 | -$7.28M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$3.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$4.27M derived: sum of 2 quarters · filed 2025-11-14 | -$4.91M 10-Q · filed 2025-11-14 | -$5.78M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$881.19K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | -$1.52M 10-Q · filed 2025-08-18 | -$2.39M derived: sum of 3 quarters · filed 2025-08-18 | -$3.27M derived: sum of 4 quarters · filed 2025-08-18 |
| 2024-03-31 | -$641.73K 10-Q · filed 2025-05-15 | -$1.51M derived: sum of 2 quarters · filed 2025-05-15 | -$2.39M derived: sum of 3 quarters · filed 2025-05-15 | -$3.22M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$871.16K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$1.75M derived: sum of 2 quarters · filed 2025-03-31 | -$2.58M derived: sum of 3 quarters · filed 2025-03-31 | -$3.01M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$876.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-15 | -$1.71M derived: sum of 2 quarters · filed 2024-11-15 | -$2.14M 10-Q · filed 2024-11-15 | |
| 2023-06-30 | -$831.05K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$1.26M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$428.19K 10-Q · filed 2024-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |